April 12, 2021

With approximately 579,811 manufacturers in the US, the industry is vast and consists of a myriad of business types that live within the various levels of the supply chain.

April 7, 2021

Past experience on improving gender diversity demonstrates that setting targets is key to driving cultural change and making tangible progress in fostering an inclusive environment.

April 6, 2021

While global headlines remain dominated with vaccine-related news, what often goes under the radar are the significant risk management considerations for vaccine sponsors and contract research organizations (CROs) working behind the scenes, leading the way at the clinical research and trial stage.

March 29, 2021

We recently commissioned research with over 370 leaders of digital health and wellness businesses around the world to help us better understand their growth ambition, their insurance buying habits, and the risks that concern them most.

March 9, 2021

New developments in the life sciences sector require the use of bespoke rather than general liabilityinsurance covers if the industry is to manage its exposures properly.

February 17, 2021

When Beazley started underwriting its miscellaneous medical risk book of business in response to the emerging demand for insurance cover by operators of blood and human tissue banks, there was no real market. These risks fell somewhere between medical professional and medical products liability.

February 9, 2021

The days of sitting in a doctor’s waiting room for hours, often surrounded by other coughing and viral patients, is already becoming a thing of the past.

February 4, 2021

As a leading cyber insurer, we have seen an upward shift in the underlying exposure and more of our clients are in need of our expert advice and support. We have invested in a number of tools to help better identify and correct vulnerabilities and have access to data, expertise and insight to address these risks proactively.

January 25, 2021

As competition to differentiate gathers pace, nutraceutical companies must prepare for the increased regulation and public scrutiny that accompanies the transition from off-the-shelf to personalized products and understand their supply chain risk exposures.